Literature DB >> 19346511

A pilot study of nicotine delivery to smokers from a metered-dose inhaler.

Brent Caldwell1, Stuart Dickson, Carl Burgess, Robert Siebers, Sima Mala, Adrienne Parkes, Julian Crane.   

Abstract

INTRODUCTION: The present study generated preliminary data on the acceptability and pharmacokinetics of nicotine administered by a simple metered-dose inhaler (MDI).
METHODS: We conducted a nonrandomized, open-label cross-over trial of 10 current smokers. On Day 1, a single cigarette was smoked ad libitum. On Day 2, participants took 10 puffs (20 inhalations) of 50 microg nicotine/puff through the inhaler, and on Day 3, they took 10 puffs (20 inhalations) of 100 microg nicotine/puff, each over 5 min. Nicotine pharmacokinetics, changes in heart rate and blood pressure, and the acceptability of the inhalers were measured and recorded.
RESULTS: Nicotine administered by an MDI produced a median maximum plasma concentration that was about 50% of that obtained by smoking a cigarette (12.5 vs. 25.9 ng/ml) and took twice the time to reach that concentration, 6 versus 3 min. Self-rated satisfaction and reduced urge to smoke were similar for the MDIs and a cigarette. DISCUSSION: The results suggest that nicotine can be delivered effectively by the pulmonary route using a standard MDI. The inhaler appears to provide a satisfaction level and reduction in the urge to smoke relatively similar to that provided by smoking a cigarette. These conclusions require verification in a larger controlled study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19346511     DOI: 10.1093/ntr/ntp027

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  7 in total

Review 1.  The reinforcement threshold for nicotine as a target for tobacco control.

Authors:  Mehmet Sofuoglu; Mark G LeSage
Journal:  Drug Alcohol Depend       Date:  2012-05-21       Impact factor: 4.492

2.  Smoker interest in lower harm alternatives to cigarettes: national survey data.

Authors:  Nick Wilson; Ron Borland; Deepa Weerasekera; Richard Edwards; Marie Russell
Journal:  Nicotine Tob Res       Date:  2009-10-14       Impact factor: 4.244

3.  Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler.

Authors:  Irina Esterlis; Effie M Mitsis; Jeffery C Batis; Frederic Bois; Marina R Picciotto; Stephanie M Stiklus; Tracy Kloczynski; Edward Perry; John P Seibyl; Sherry McKee; Julie K Staley; Kelly P Cosgrove
Journal:  Int J Neuropsychopharmacol       Date:  2010-10-29       Impact factor: 5.176

Review 4.  Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: rationale, and evidence for advantages over existing systems.

Authors:  Lion Shahab; Leonie S Brose; Robert West
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

5.  Acute and chronic sympathomimetic effects of e-cigarette and tobacco cigarette smoking: role of nicotine and non-nicotine constituents.

Authors:  Sara Arastoo; Kacey P Haptonstall; Yasmine Choroomi; Roya Moheimani; Kevin Nguyen; Elizabeth Tran; Jeffrey Gornbein; Holly R Middlekauff
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-06-19       Impact factor: 5.125

6.  Evaluation of a novel nicotine inhaler device: part 1--arterial and venous pharmacokinetics.

Authors:  Chris Moyses; Alex Hearn; Andrew Redfern
Journal:  Nicotine Tob Res       Date:  2014-11-10       Impact factor: 4.244

7.  Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Delivery System.

Authors:  Axel Teichert; Patrick Brossard; Loyse Felber Medlin; Larissa Sandalic; Mikael Franzon; Chris Wynne; Murray Laugesen; Frank Lüdicke
Journal:  Nicotine Tob Res       Date:  2018-03-06       Impact factor: 4.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.